Jyunka Hayashi
Gyoda, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes.
Journal: Drug research
Published: November 26, 2020
Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin.
Journal: Hospital practice (1995)
Published: November 16, 2020
Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy.
Journal: Hospital practice (1995)
Published: February 27, 2020
Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function .
Journal: International journal of clinical pharmacology and therapeutics
Published: October 08, 2019
Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.
Journal: Endocrine regulations
Published: September 14, 2019
Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
Journal: Drugs in R&D
Published: October 17, 2018
Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.
Journal: Drug research
Published: October 09, 2018
REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: October 06, 2018
Characterization of Metabolic Parameters in Responders and Nonresponders Treated with Canagliflozin Monotherapy in Drug-naive Subjects with Type 2 Diabetes.
Journal: Indian journal of endocrinology and metabolism
Published: June 19, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026